Literature DB >> 12454108

Clinicopathologic correlations of genomic gains and losses in follicular lymphoma.

Andreas Viardot1, Peter Möller, Josef Högel, Kirsten Werner, Gunhild Mechtersheimer, Anthony D Ho, German Ott, Thomas F E Barth, Reiner Siebert, Stefan Gesk, Brigitte Schlegelberger, Hartmut Döhner, Martin Bentz.   

Abstract

PURPOSE: To evaluate the clinical relevance of genomic aberrations in follicular lymphomas (FLs). PATIENTS AND METHODS: In this study, we analyzed 124 biopsy samples of patients with FL using comparative genomic hybridization.
RESULTS: In 87 cases (70%), genomic imbalances were detectable. The most frequent aberrations were gains of chromosome arms 7p (21 patients), 7q (21 patients), Xp (16 patients), 12q (15 patients), and 18q (14 patients) as well as losses on 6q (21 patients). Grades 2 and 3 according to the World Health Organization classification correlated with a more complex karyotype (P <.0001). In a subset of 82 patients, a comprehensive clinical data set was available. In a multivariate analysis including all clinical risk factors of the International Prognostic Index as well as genomic aberrations, the loss of material on chromosomal bands 6q25q27 was the strongest predictor of a shorter survival (P =.0001; hazard ratio, 6.5), followed by elevated serum lactate dehydrogenase level (P =.0009; hazard ratio, 4.9), the presence of more than one extranodal manifestation (P =.017; hazard ratio, 4.2), and age greater than 60 years (P =.022; hazard ratio, 2.6).
CONCLUSION: These data indicate that genomic aberrations may contribute significantly to risk assessment in patients with FL, the majority of whom are included in low-risk groups using established clinical prognostic scores.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12454108     DOI: 10.1200/JCO.2002.12.006

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

Review 1.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

2.  Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.

Authors:  Derville O'Shea; Ciarán O'Riain; Manu Gupta; Rachel Waters; Youwen Yang; David Wrench; John Gribben; Andreas Rosenwald; German Ott; Lisa M Rimsza; Harald Holte; Jean-Baptiste Cazier; Nathalie A Johnson; Elias Campo; Wing C Chan; Randy D Gascoyne; Bryan D Young; Louis M Staudt; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 3.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

4.  The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma.

Authors:  Elisa Oricchio; Gouri Nanjangud; Andrew L Wolfe; Jonathan H Schatz; Konstantinos J Mavrakis; Man Jiang; Xiaoping Liu; Joanne Bruno; Adriana Heguy; Adam B Olshen; Nicholas D Socci; Julie Teruya-Feldstein; Frances Weis-Garcia; Wayne Tam; Rita Shaknovich; Ari Melnick; Juha P Himanen; R S K Chaganti; Hans-Guido Wendel
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

5.  Activating STAT6 mutations in follicular lymphoma.

Authors:  Mehmet Yildiz; Hongxiu Li; Denzil Bernard; Nisar A Amin; Peter Ouillette; Siân Jones; Kamlai Saiya-Cork; Brian Parkin; Kathryn Jacobi; Kerby Shedden; Shaomeng Wang; Alfred E Chang; Mark S Kaminski; Sami N Malek
Journal:  Blood       Date:  2014-11-26       Impact factor: 22.113

6.  Predictive value of prognostic indices in patients with follicular lymphomas.

Authors:  M Radojkovic; S Ristic; M Colovic; B Mihaljevic; V Cemerikic-Martinovic
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

7.  Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature.

Authors:  Itziar Salaverria; Andreas Zettl; Sílvia Beà; Victor Moreno; Joan Valls; Elena Hartmann; German Ott; George Wright; Armando Lopez-Guillermo; Wing C Chan; Dennis D Weisenburger; Randy D Gascoyne; Thomas M Grogan; Jan Delabie; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Andreas Rosenwald; Elias Campo
Journal:  J Clin Oncol       Date:  2007-02-12       Impact factor: 44.544

8.  Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.

Authors:  Hongxiu Li; Mark S Kaminski; Yifeng Li; Mehmet Yildiz; Peter Ouillette; Siân Jones; Heather Fox; Kathryn Jacobi; Kamlai Saiya-Cork; Dale Bixby; Daniel Lebovic; Diane Roulston; Kerby Shedden; Michael Sabel; Lawrence Marentette; Vincent Cimmino; Alfred E Chang; Sami N Malek
Journal:  Blood       Date:  2014-01-16       Impact factor: 22.113

9.  Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.

Authors:  Zhang Xiao Ying; Meiyan Jin; Luke F Peterson; Denzil Bernard; Kamlai Saiya-Cork; Mehmet Yildiz; Shaomeng Wang; Mark S Kaminski; Alfred E Chang; Daniel J Klionsky; Sami N Malek
Journal:  Clin Cancer Res       Date:  2016-06-07       Impact factor: 12.531

10.  Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.

Authors:  Imran N Siddiqi; Julia Friedman; Keegan Q Barry-Holson; Charles Ma; Venkata Thodima; Irene Kang; Raghavendra Padmanabhan; Lizalynn M Dias; Kevin R Kelly; Russell K Brynes; Sitharthan Kamalakaran; Jane Houldsworth
Journal:  Mod Pathol       Date:  2016-03-11       Impact factor: 8.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.